论文部分内容阅读
目的检测雄激素受体(AR)、ki-67、P53、环氧化酶-2(COX-2)和表皮生长因子受体(EGFR)在前列腺癌的表达,探讨其表达对前列腺癌患者术后预后的影响及其临床意义。方法收集2008年1月至2014年10月的前列腺癌患者40例,年龄51~83岁,平均70岁,免疫组化法检测前列腺肿瘤组织中AR、ki-67、P53、COX-2和EGFR的表达,对患者进行随访,应用SPSS 16.0统计学软件进行统计学分析,用Cox比例风险回归模型进行预后分析。结果免疫组织化学结果显示,40例前列腺癌标本中,AR(+)36例(90.0%),ki-67(+)20例(50.0)%,P53(+)17例(42.5%),COX-2(+)21例(52.5%),EFGR(+)26例(65.0%)。随访结束时,12例出现生化复发。COX-2阴性组较阳性组生化复发率低,差异有统计学意义(P=0.032)。结论 COX-2为前列腺癌患者预后的危险因素。
Objective To detect the expression of androgen receptor (AR), ki-67, P53, cyclooxygenase-2 (COX-2) and epidermal growth factor receptor (EGFR) in prostate cancer and to explore their expression on patients with prostate cancer Prognosis and its clinical significance. Methods Forty patients with prostate cancer from January 2008 to October 2014 were collected, ranging in age from 51 to 83 years with a mean of 70 years. The expressions of AR, ki-67, P53, COX-2 and EGFR in prostate cancer tissues were detected by immunohistochemistry The patients were followed up. Statistical analysis was performed using SPSS 16.0 statistical software and Cox proportional hazards regression model was used for prognostic analysis. Results Immunohistochemical results showed that there were 36 cases (90.0%) of AR (+), 20 cases (50.0)% of ki-67 (+) and 17 cases (42.5%) of P53 21 cases (52.5%) of -2 (+) and 26 cases (65.0%) of EFGR (+). At the end of follow-up, biochemical relapse occurred in 12 patients. The rate of biochemical recurrence in COX-2 negative group was lower than that in positive group, the difference was statistically significant (P = 0.032). Conclusions COX-2 is a risk factor for the prognosis of patients with prostate cancer.